Latest total revenue for ZSAN: $660K, below the Healthcare sector average of $110B.
Get informed when a big investor buys or sells
+ FollowAs of Mar 2022
Trailing 12 months ending Mar 2022
The latest total revenue for ZSAN is $660K as of March 2022. That compares with $480K in the prior-year period — up 36.7% year over year. That is below the Healthcare sector average of $110B. Investors often review this figure alongside Zosano Pharma's historical trend and sector peers before judging valuation or financial health.
Over the past year, ZSAN's total revenue moved from $480K to $660K — a 36.7% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Zosano Pharma's operating scale or balance-sheet position.
Against Healthcare companies, ZSAN currently prints $660K for total revenue, while the sector average sits near $110B. That is roughly 100.0% below the sector mean. Large gaps often invite a closer look at Zosano Pharma's growth, margins, and balance sheet.
A total revenue figure of $660K for ZSAN is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $110B. Explore the charts below for those layers of context.
After noting ZSAN's total revenue ($660K), review year-over-year change from $480K, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.